827 related articles for article (PubMed ID: 35561224)
21. Measles Virus-Based Vaccine Expressing Membrane-Anchored Spike of SARS-CoV-2 Inducing Efficacious Systemic and Mucosal Humoral Immunity in Hamsters.
Yang ZH; Song YL; Pei J; Li SZ; Liu RL; Xiong Y; Wu J; Liu YL; Fan HF; Wu JH; Wang ZJ; Guo J; Meng SL; Chen XQ; Lu J; Shen S
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675901
[TBL] [Abstract][Full Text] [Related]
22. High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens.
Counoupas C; Pino P; Stella AO; Ashley C; Lukeman H; Bhattacharyya ND; Tada T; Anchisi S; Metayer C; Martinis J; Aggarwal A; Dcosta BM; Britton WJ; Kint J; Wurm MJ; Landau NR; Steain M; Turville SG; Wurm FM; David SA; Triccas JA
Microbiol Spectr; 2022 Feb; 10(1):e0169521. PubMed ID: 35171046
[TBL] [Abstract][Full Text] [Related]
23. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
Xu J; Zhang Y; Qu P; Shamseldin MM; Yoo SJ; Misny J; Thongpan I; Kc M; Hall JM; Evans JP; Eltobgy M; Lu M; Ye C; Chamblee M; Liang X; Martinez-Sobrido L; Amer AO; Yount JS; Boyaka PN; Peeples ME; Liu SL; Dubey P; Li J
Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2220403120. PubMed ID: 37796985
[TBL] [Abstract][Full Text] [Related]
24. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
25. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
[TBL] [Abstract][Full Text] [Related]
27. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.
Channappanavar R; Fett C; Zhao J; Meyerholz DK; Perlman S
J Virol; 2014 Oct; 88(19):11034-44. PubMed ID: 25056892
[TBL] [Abstract][Full Text] [Related]
28. Cross-protection induced by highly conserved human B, CD4
Prakash S; Dhanushkodi NR; Zayou L; Ibraim IC; Quadiri A; Coulon PG; Tifrea DF; Suzer B; Shaik AM; Chilukuri A; Edwards RA; Singer M; Vahed H; Nesburn AB; Kuppermann BD; Ulmer JB; Gil D; Jones TM; BenMohamed L
Front Immunol; 2024; 15():1328905. PubMed ID: 38318166
[TBL] [Abstract][Full Text] [Related]
29. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
[TBL] [Abstract][Full Text] [Related]
30. Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
Pal R; Ferrari MG; Honda-Okubo Y; Wattay L; Caple J; Navarrete J; Andersen H; Petrovsky N
Vaccine; 2024 Feb; 42(5):1122-1135. PubMed ID: 38262808
[TBL] [Abstract][Full Text] [Related]
31. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
32. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Sahin U; Muik A; Vogler I; Derhovanessian E; Kranz LM; Vormehr M; Quandt J; Bidmon N; Ulges A; Baum A; Pascal KE; Maurus D; Brachtendorf S; Lörks V; Sikorski J; Koch P; Hilker R; Becker D; Eller AK; Grützner J; Tonigold M; Boesler C; Rosenbaum C; Heesen L; Kühnle MC; Poran A; Dong JZ; Luxemburger U; Kemmer-Brück A; Langer D; Bexon M; Bolte S; Palanche T; Schultz A; Baumann S; Mahiny AJ; Boros G; Reinholz J; Szabó GT; Karikó K; Shi PY; Fontes-Garfias C; Perez JL; Cutler M; Cooper D; Kyratsous CA; Dormitzer PR; Jansen KU; Türeci Ö
Nature; 2021 Jul; 595(7868):572-577. PubMed ID: 34044428
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
Carnell GW; Ciazynska KA; Wells DA; Xiong X; Aguinam ET; McLaughlin SH; Mallery D; Ebrahimi S; Ceron-Gutierrez L; Asbach B; Einhauser S; Wagner R; James LC; Doffinger R; Heeney JL; Briggs JAG
J Virol; 2021 Jul; 95(15):e0020321. PubMed ID: 33963055
[TBL] [Abstract][Full Text] [Related]
34. mRNA-LNP vaccine-induced CD8
Montoya B; Melo-Silva CR; Tang L; Kafle S; Lidskiy P; Bajusz C; Vadovics M; Muramatsu H; Abraham E; Lipinszki Z; Chatterjee D; Scher G; Benitez J; Sung MMH; Tam YK; Catanzaro NJ; Schäfer A; Andino R; Baric RS; Martinez DR; Pardi N; Sigal LJ
Mol Ther; 2024 Jun; 32(6):1790-1804. PubMed ID: 38605519
[TBL] [Abstract][Full Text] [Related]
35. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020).
Kim DS; Rowland-Jones S; Gea-Mallorquí E
Front Immunol; 2020; 11():571481. PubMed ID: 33362759
[TBL] [Abstract][Full Text] [Related]
36. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
37. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
38. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
Front Immunol; 2022; 13():816220. PubMed ID: 35145522
[TBL] [Abstract][Full Text] [Related]
39. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses.
Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson SC; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer DE; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA;
Cell Rep; 2022 Feb; 38(6):110345. PubMed ID: 35090598
[TBL] [Abstract][Full Text] [Related]
40. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
Honda-Okubo Y; Bowen R; Barker M; Bielefeldt-Ohmann H; Petrovsky N
Vaccine; 2023 Nov; 41(48):7116-7128. PubMed ID: 37863669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
